<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>AMICAR- aminocaproic acid solution </strong><br><strong>AMICAR- aminocaproic acid tablet </strong><br>Clover Pharmaceuticals Corp.<br></p></div>
<h1>
<span class="Bold">AMICAR<span class="Sup">®</span> (aminocaproic acid)</span><br><span class="Bold"> Oral Solution and Tablets</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1ef7238a-b2eb-4e7c-b28f-0284c88fe822"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">R<span class="Sub">x</span> only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_c71a5a0c-5953-4571-9b82-42ab33d68e7b"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">AMICAR (aminocaproic acid) is 6-aminohexanoic acid, which acts as an inhibitor of <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span>.</p>
<p>Its chemical structure is:</p>
<div class="Figure">
<a name="id-145903807"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2238c70f-b0b5-4755-896b-45b28777b217&amp;name=image-01.jpg">
</div>
<p>AMICAR is soluble in water, acid, and alkaline solutions; it is sparingly soluble in methanol and practically insoluble in chloroform.</p>
<p>AMICAR (aminocaproic acid) Oral Solution for oral administration, contains 0.25 g/mL of aminocaproic acid with methylparaben 0.20%, propylparaben 0.05%, edetate disodium 0.30% as preservatives and the following inactive ingredients: sodium saccharin, sorbitol solution, citric acid anhydrous, natural and artificial raspberry flavor and an artificial bitterness modifier.</p>
<p>Each AMICAR (aminocaproic acid) Tablet, for oral administration contains 500 mg or 1000 mg of aminocaproic acid and the following inactive ingredients: povidone, crospovidone, stearic acid, and magnesium stearate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_f1f24186-1617-4e70-b83a-675df4f89101"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">The <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span>-inhibitory effects of AMICAR appear to be exerted principally via inhibition of <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> activators and to a lesser degree through antiplasmin activity.</p>
<p>In adults, oral absorption appears to be a zero-order process with an absorption rate of 5.2 g/hr. The mean lag time in absorption is 10 minutes. After a single oral dose of 5 g, absorption was complete (F=1). Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.</p>
<p>After oral administration, the apparent volume of distribution was estimated to be 23.1 ± 6.6 L (mean ± SD). Correspondingly, the volume of distribution after intravenous administration has been reported to be 30.0 ± 8.2 L. After prolonged administration, AMICAR has been found to distribute throughout extravascular and intravascular compartments of the body, penetrating human red blood cells as well as other tissue cells.</p>
<p>Renal excretion is the primary route of elimination. Sixty-five percent of the dose is recovered in the urine as unchanged drug and 11% of the dose appears as the metabolite adipic acid. Renal clearance (116 mL/min) approximates endogenous creatinine clearance. The total body clearance is 169 mL/min. The terminal elimination half-life for AMICAR is approximately 2 hours.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_74156542-c557-483e-9acb-51dae4a4e447"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">AMICAR is useful in enhancing hemostasis when <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span> contributes to <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required.</p>
<p>Fibrinolytic <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (accompanying <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>); acute and life-threatening <span class="product-label-link" type="condition" conceptid="198488" conceptname="Placental abruption">abruptio placentae</span>; <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span>; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix.</p>
<p>Urinary <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span>, usually a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> associated with surgical <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> (following prostatectomy and nephrectomy) or nonsurgical <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> (accompanying polycystic or neoplastic diseases of the genitourinary system). (See <span class="Bold"><a href="#i4i_warnings_id_ef34ef64-9888-434e-a176-3b7d765b6eb8">WARNINGS</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_3faf40ed-904d-4be9-bb7e-81d62840ba00"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">AMICAR should not be used when there is evidence of an active intravascular clotting process.</p>
<p>When there is uncertainty as to whether the cause of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is primary <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span> or <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span> (DIC), this distinction must be made before administering AMICAR.</p>
<p>The following tests can be applied to differentiate the two conditions:</p>
<p>Platelet count is usually decreased in DIC but normal in primary <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span>.</p>
<p>Protamine paracoagulation test is positive in DIC; a precipitate forms when protamine sulfate is dropped into citrated plasma. The test is negative in the presence of primary <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span>.</p>
<p>The euglobulin clot lysis test is abnormal in primary <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span> but normal in DIC.</p>
<p>AMICAR must not be used in the presence of DIC without concomitant heparin.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_ef34ef64-9888-434e-a176-3b7d765b6eb8"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">In patients with upper urinary tract <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, AMICAR administration has been known to cause intrarenal obstruction in the form of glomerular capillary <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> or clots in the renal pelvis and ureters. For this reason, AMICAR should not be used in <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> of upper urinary tract origin, unless the possible benefits outweigh the risk.</p>
<p>Subendocardial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span> have been observed in dogs given intravenous infusions of 0.2 times the maximum human therapeutic dose of AMICAR and in monkeys given 8 times the maximum human therapeutic dose of AMICAR.</p>
<p>Fatty degeneration of the myocardium has been reported in dogs given intravenous doses of AMICAR at 0.8 to 3.3 times the maximum human therapeutic dose and in monkeys given intravenous doses of AMICAR at 6 times the maximum human therapeutic dose.</p>
<p>Rarely, skeletal <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> with <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> of muscle fibers has been reported following prolonged administration. Clinical presentation may range from mild <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span> with <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> to a severe <span class="product-label-link" type="condition" conceptid="4102023" conceptname="Proximal myopathy">proximal myopathy</span> with <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span>, and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>. Muscle enzymes, especially creatine phosphokinase (CPK) are elevated. CPK levels should be monitored in patients on long-term therapy. AMICAR administration should be stopped if a rise in CPK is noted. Resolution follows discontinuation of AMICAR; however, the syndrome may recur if AMICAR is restarted.</p>
<p>The possibility of cardiac <span class="product-label-link" type="condition" conceptid="4048093" conceptname="Hamstring injury">muscle damage</span> should also be considered when skeletal <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> occurs. One case of cardiac and <span class="product-label-link" type="condition" conceptid="4104000" conceptname="Lesion of liver">hepatic lesions</span> observed in man has been reported. The patient received 2 g of aminocaproic acid every 6 hours for a total dose of 26 g. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> was due to continued cerebrovascular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>. Necrotic changes in the heart and liver were noted at autopsy.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_cb4594e0-e7fe-4f9d-865a-7b2978388d33"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_e7d77822-dd3d-41a9-9f0e-00e53731eefd"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">AMICAR inhibits both the action of <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> activators and to a lesser degree, plasmin activity. The drug should NOT be administered without a definite diagnosis and/or laboratory finding indicative of hyperfibrinolysis (hyperplasminemia).<span class="Sup">1</span> Inhibition of <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span> by aminocaproic acid may theoretically result in clotting or <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>. However, there is no definite evidence that administration of aminocaproic acid has been responsible for the few reported cases of intravascular clotting which followed this treatment. Rather, it appears that such intravascular clotting was most likely due to the patient's preexisting clinical condition, e.g., the presence of DIC. It has been postulated that extravascular clots formed <span class="Italics">in vivo</span> may not undergo spontaneous lysis as do normal clots.</p>
<p>Reports have appeared in the literature of an increased incidence of certain neurological deficits such as <span class="product-label-link" type="condition" conceptid="4043738" conceptname="Hydrocephalus">hydrocephalus</span>, <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span>, or cerebral <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> associated with the use of antifibrinolytic agents in the treatment of <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span> (SAH). All of these events have also been described as part of the natural course of SAH, or as a consequence of diagnostic procedures such as angiography. Drug relatedness remains unclear.</p>
<p>Aminocaproic acid should not be administered with Factor IX Complex concentrates or Anti-Inhibitor Coagulant concentrates, as the risk of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> may be increased.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_307469ed-52ec-40cd-865f-5fa777740377"></a><a name="section-7.2"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">The use of AMICAR should be accompanied by tests designed to determine the amount of <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span> present. There are presently available: (a) general tests such as those for the determination of the lysis of a clot of blood or plasma; and (b) more specific tests for the study of various phases of the fibrinolytic mechanisms. These latter tests include both semiquantitative and quantitative techniques for the determination of profibrinolysin, fibrinolysin, and antifibrinolysin.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_id_b426e9c5-14f9-4c50-8019-1c03a9c6776e"></a><a name="section-7.3"></a><p></p>
<h2>Drug Laboratory Test Interactions</h2>
<p class="First">Prolongation of the template <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> has been reported during continuous intravenous infusion of AMICAR at dosages exceeding 24 g/day. Platelet function studies in these patients have not demonstrated any significant platelet dysfunction. However, <span class="Italics">in vitro</span> studies have shown that at high concentrations (7.4 mMol/L or 0.97 mg/mL and greater) aminocaproic acid inhibits ADP and collagen-induced platelet aggregation, the release of ATP and serotonin, and the binding of fibrinogen to the platelets in a concentration-response manner. Following a 10 g bolus of AMICAR, transient peak plasma concentrations of 4.6 mMol/L or 0.60 mg/mL have been obtained. The concentration of AMICAR necessary to maintain inhibition of <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span> is 0.99 mMol/L or 0.13 mg/mL. Administration of a 5 g bolus followed by 1 to 1.25 g/hr should achieve and sustain plasma levels of 0.13 mg/mL. Thus, concentrations which have been obtained <span class="Italics">in vivo</span> clinically in patients with normal renal function are considerably lower than the <span class="Italics">in vitro</span> concentrations found to induce abnormalities in platelet function tests. However, higher plasma concentrations of AMICAR may occur in patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_e497fa4a-013c-4ef8-b0da-4791a83b2e3a"></a><a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies in animals to evaluate the carcinogenic potential of AMICAR and studies to evaluate its mutagenic potential have not been conducted. Dietary administration of an equivalent of the maximum human therapeutic dose of AMICAR to rats of both sexes impaired fertility as evidenced by decreased implantations, litter sizes and number of pups born.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_96ceef5c-2761-40c7-a940-ae834bb3abe4"></a><a name="section-7.5"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"><span class="Italics">Pregnancy Category C.</span> Animal reproduction studies have not been conducted with AMICAR. It is also not known whether AMICAR can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. AMICAR should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_0092db08-5c96-4cbb-863e-2db70ea70455"></a><a name="section-7.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when AMICAR is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_39567bb7-2f42-4d35-80cf-16adaa045f4f"></a><a name="section-7.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_27cf4785-e11f-4b42-b077-c1f095495323"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">AMICAR is generally well tolerated. The following adverse experiences have been reported:</p>
<p><span class="Bold">General:</span> <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>:</span> Allergic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>.</p>
<p><span class="Bold">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4124836" conceptname="Peripheral ischemia">peripheral ischemia</span>, <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>.</p>
<p><span class="Bold">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p><span class="Bold">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorder</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="Bold">Musculoskeletal:</span> CPK increased, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> (see <span class="Bold"><a href="#i4i_warnings_id_ef34ef64-9888-434e-a176-3b7d765b6eb8">WARNINGS</a></span>), <span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span>, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>.</p>
<p><span class="Bold">Neurologic:</span> <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">intracranial hypertension</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</p>
<p><span class="Bold">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>.</p>
<p><span class="Bold">Skin:</span> Pruritis, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
<p><span class="Bold">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span>, <span class="product-label-link" type="condition" conceptid="376402" conceptname="Low vision, one eye">vision decreased</span>, watery eyes.</p>
<p><span class="Bold">Urogenital:</span> BUN increased, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>. There have been some reports of dry ejaculation during the period of AMICAR treatment. These have been reported to date only in <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span> patients who received the drug after undergoing dental surgical procedures. However, this symptom resolved in all patients within 24 to 48 hours of completion of therapy.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_b604dc03-5d51-4e46-ba57-8fe9aeb94b89"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">A few cases of acute overdosage with AMICAR administered intravenously have been reported. The effects have ranged from no reaction to transient <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> to severe <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. One patient with a history of <span class="product-label-link" type="condition" conceptid="4116092" conceptname="Intracranial tumor">brain tumor</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> experienced <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> after receiving an 8 gram bolus injection of AMICAR. The single dose of AMICAR causing symptoms of overdosage or considered to be life-threatening is unknown. Patients have tolerated doses as high as 100 grams while <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> has been reported following a dose of 12 grams.</p>
<p>The intravenous and oral LD<span class="Sub">50</span> of AMICAR were 3.0 and 12.0 g/kg, respectively, in the mouse and 3.2 and 16.4 g/kg, respectively, in the rat. An intravenous infusion dose of 2.3 g/kg was lethal in the dog. On intravenous administration, tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic convulsions</span> were observed in dogs and mice.</p>
<p>No treatment for overdosage is known, although evidence exists that AMICAR is removed by hemodialysis and may be removed by peritoneal dialysis. Pharmacokinetic studies have shown that total body clearance of AMICAR is markedly decreased in patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_f76073a6-b892-4788-a5cc-99d965094a58"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">An identical dosage regimen may be followed by administering AMICAR Tablets or AMICAR Oral Solution as follows:</p>
<p>For the treatment of acute <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> syndromes due to elevated fibrinolytic activity, it is suggested that 5 AMICAR 1000 mg Tablets or 10 AMICAR 500 mg Tablets (5 g) or 20 milliliter of AMICAR Oral Solution (5 g) be administered during the first hour of treatment, followed by a continuing rate of 1 AMICAR 1000 mg Tablet or 2 AMICAR 500 mg Tablets (1 g) or 5 milliliter of AMICAR Oral Solution (1.25 g) per hour. This method of treatment would ordinarily be continued for about 8 hours or until the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> situation has been controlled.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_ee28a58f-ebea-457c-aa4e-b02409869603"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">AMICAR<span class="Sup">® </span><br>(aminocaproic acid) </p>
<p><span class="Bold">AMICAR Oral Solution, 0.25 g/mL</span></p>
<p>Each mL of raspberry-flavored oral solution contains 0.25 g/mL of aminocaproic acid. </p>
<p>8 Fl. Oz. (236.5 mL) Bottle – NDC 49411-052-08</p>
<p><span class="Italics">Store at 20°-25°C (68°-77°F)[see USP Controlled Room Temperature];Dispense in Tight Containers; Do Not Freeze.</span></p>
<p><span class="Bold">AMICAR 500 mg Tablets</span></p>
<p>Each round, white tablet, engraved with XP on one side and scored on the other with A to the left of the score and 10 on the right, contains 500 mg of aminocaproic acid. </p>
<p>Bottle of 30 – NDC 49411-050-30</p>
<p><span class="Italics">Store at 20°-25°C (68°-77°F)[see USP Controlled Room Temperature];Dispense in Tight Containers; Do Not Freeze.</span></p>
<p><span class="Bold">AMICAR 1000 mg Tablets</span></p>
<p>Each oblong, white tablet, engraved with XP on one side and scored on the other with A to the left of the score and 20 on the right, contains 1000 mg of aminocaproic acid. </p>
<p>Bottle of 30 – NDC 49411-051-30</p>
<p><span class="Italics">Store at 20°-25°C (68°-77°F)[see USP Controlled Room Temperature];Dispense in Tight Containers; Do Not Freeze.</span></p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_82b28369-38db-4c7c-91a8-3525276adede"></a><a name="section-12"></a><p></p>
<h1>REFERENCE</h1>
<p class="First"><span class="Sup">1</span> Stefanini M, Dameshek W: <span class="Italics">The <span class="product-label-link" type="condition" conceptid="432869" conceptname="Hemorrhagic disorder due to circulating anticoagulants">Hemorrhagic Disorders</span>,</span> Ed. 2, New York, Grune and Stratton; 1962:510-514.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b871fdaf-26de-402b-b6cb-716ab4829681"></a><a name="section-13"></a><p></p>
<p class="First">Marketed by <br><a name="id-1405215907"></a><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2238c70f-b0b5-4755-896b-45b28777b217&amp;name=image-02.jpg"><br>Marietta, GA 30062</p>
<p>Code 909B00<br>Rev. 05/15</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_bd005227-a11d-419b-962a-eeb162b7cda4"></a><a name="section-14"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</h1>
<p class="First">Bottle Label – 8 Fl. Oz. (236.5 mL)<br>NDC 49411-052-08<br><span class="Bold">AMICAR<span class="Sup">®</span></span><br><span class="Bold">Aminocaproic Acid</span><br><span class="Bold">Oral Solution</span><br><span class="Bold">0.25 grams/mL</span><br><span class="Bold">Rx only</span><br>8 Fl. Oz. (236.5 mL)</p>
<div class="Figure">
<a name="id338437212"></a><img alt="Bottle Label – 8 Fl. Oz. (236.5 mL)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2238c70f-b0b5-4755-896b-45b28777b217&amp;name=9ce611a6-1000-4b17-bfe2-3ab2771285ba-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_0c53d211-78f4-44fe-8ae2-77d06ddd817c"></a><a name="section-15"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</h1>
<p class="First">Bottle Label – 500 mg<br>NDC 49411-050-30<br><span class="Bold">500 mg</span><br><span class="Bold">AMICAR<span class="Sup">®</span></span><br><span class="Bold">Aminocaproic Acid</span><br><span class="Bold">Tablets</span><br><span class="Bold">Rx Only</span><br><span class="Bold">30 Tablets </span></p>
<div class="Figure">
<a name="id-1646812951"></a><img alt="Bottle Label-500 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2238c70f-b0b5-4755-896b-45b28777b217&amp;name=9ce611a6-1000-4b17-bfe2-3ab2771285ba-04.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_12ad9c23-a455-4ebf-9396-5c72a31fe6f1"></a><a name="section-16"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</h1>
<p class="First">Bottle Label – 1000 mg<br>NDC 49411-051-30<br><span class="Bold">1000 mg</span><br><span class="Bold">AMICAR<span class="Sup">®</span></span><br><span class="Bold">Aminocaproic Acid</span><br><span class="Bold">Tablets</span><br><span class="Bold">Rx Only</span><br><span class="Bold">30 Tablets</span></p>
<div class="Figure">
<a name="id27536283"></a><img alt="Bottle Label-1000 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2238c70f-b0b5-4755-896b-45b28777b217&amp;name=9ce611a6-1000-4b17-bfe2-3ab2771285ba-05.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMICAR 		
					</strong><br><span class="contentTableReg">aminocaproic acid solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49411-052</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMINOCAPROIC ACID</strong> (AMINOCAPROIC ACID) </td>
<td class="formItem">AMINOCAPROIC ACID</td>
<td class="formItem">0.25 g  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ANHYDROUS CITRIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>RASPBERRY</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">RASPBERRY (RASPBERRY) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49411-052-08</td>
<td class="formItem">236.5 mL in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem">06/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA015230</td>
<td class="formItem">06/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMICAR 		
					</strong><br><span class="contentTableReg">aminocaproic acid tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49411-050</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMINOCAPROIC ACID</strong> (AMINOCAPROIC ACID) </td>
<td class="formItem">AMINOCAPROIC ACID</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (WHITE) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">XP;A;10</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49411-050-30</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem">06/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA015197</td>
<td class="formItem">06/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMICAR 		
					</strong><br><span class="contentTableReg">aminocaproic acid tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49411-051</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMINOCAPROIC ACID</strong> (AMINOCAPROIC ACID) </td>
<td class="formItem">AMINOCAPROIC ACID</td>
<td class="formItem">1000 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (WHITE) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">XP;A;20</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49411-051-30</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem">06/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA015197</td>
<td class="formItem">06/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Clover Pharmaceuticals Corp.
							(078398998)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>bba3bfb1-b56e-4370-8b68-25f18db3fc02</div>
<div>Set id: 2238c70f-b0b5-4755-896b-45b28777b217</div>
<div>Version: 4</div>
<div>Effective Time: 20150611</div>
</div>
</div> <div class="DistributorName">Clover Pharmaceuticals Corp.</div></p>
</body></html>
<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>AMICAR- aminocaproic acid solution </strong><br><strong>AMICAR- aminocaproic acid tablet </strong><br>Clover Pharmaceuticals Corp.<br></p></div>
<h1>
<span class="Bold">AMICAR<span class="Sup">®</span> (aminocaproic acid)</span><br><span class="Bold"> Oral Solution and Tablets</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1ef7238a-b2eb-4e7c-b28f-0284c88fe822"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">R<span class="Sub">x</span> only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_c71a5a0c-5953-4571-9b82-42ab33d68e7b"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">AMICAR (aminocaproic acid) is 6-aminohexanoic acid, which acts as an inhibitor of <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span>.</p>
<p>Its chemical structure is:</p>
<div class="Figure">
<a name="id-145903807"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2238c70f-b0b5-4755-896b-45b28777b217&amp;name=image-01.jpg">
</div>
<p>AMICAR is soluble in water, acid, and alkaline solutions; it is sparingly soluble in methanol and practically insoluble in chloroform.</p>
<p>AMICAR (aminocaproic acid) Oral Solution for oral administration, contains 0.25 g/mL of aminocaproic acid with methylparaben 0.20%, propylparaben 0.05%, edetate disodium 0.30% as preservatives and the following inactive ingredients: sodium saccharin, sorbitol solution, citric acid anhydrous, natural and artificial raspberry flavor and an artificial bitterness modifier.</p>
<p>Each AMICAR (aminocaproic acid) Tablet, for oral administration contains 500 mg or 1000 mg of aminocaproic acid and the following inactive ingredients: povidone, crospovidone, stearic acid, and magnesium stearate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_f1f24186-1617-4e70-b83a-675df4f89101"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">The <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span>-inhibitory effects of AMICAR appear to be exerted principally via inhibition of <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> activators and to a lesser degree through antiplasmin activity.</p>
<p>In adults, oral absorption appears to be a zero-order process with an absorption rate of 5.2 g/hr. The mean lag time in absorption is 10 minutes. After a single oral dose of 5 g, absorption was complete (F=1). Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.</p>
<p>After oral administration, the apparent volume of distribution was estimated to be 23.1 ± 6.6 L (mean ± SD). Correspondingly, the volume of distribution after intravenous administration has been reported to be 30.0 ± 8.2 L. After prolonged administration, AMICAR has been found to distribute throughout extravascular and intravascular compartments of the body, penetrating human red blood cells as well as other tissue cells.</p>
<p>Renal excretion is the primary route of elimination. Sixty-five percent of the dose is recovered in the urine as unchanged drug and 11% of the dose appears as the metabolite adipic acid. Renal clearance (116 mL/min) approximates endogenous creatinine clearance. The total body clearance is 169 mL/min. The terminal elimination half-life for AMICAR is approximately 2 hours.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_74156542-c557-483e-9acb-51dae4a4e447"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">AMICAR is useful in enhancing hemostasis when <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span> contributes to <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required.</p>
<p>Fibrinolytic <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (accompanying <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>); acute and life-threatening <span class="product-label-link" type="condition" conceptid="198488" conceptname="Placental abruption">abruptio placentae</span>; <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span>; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix.</p>
<p>Urinary <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span>, usually a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> associated with surgical <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> (following prostatectomy and nephrectomy) or nonsurgical <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> (accompanying polycystic or neoplastic diseases of the genitourinary system). (See <span class="Bold"><a href="#i4i_warnings_id_ef34ef64-9888-434e-a176-3b7d765b6eb8">WARNINGS</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_3faf40ed-904d-4be9-bb7e-81d62840ba00"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">AMICAR should not be used when there is evidence of an active intravascular clotting process.</p>
<p>When there is uncertainty as to whether the cause of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is primary <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span> or <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span> (DIC), this distinction must be made before administering AMICAR.</p>
<p>The following tests can be applied to differentiate the two conditions:</p>
<p>Platelet count is usually decreased in DIC but normal in primary <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span>.</p>
<p>Protamine paracoagulation test is positive in DIC; a precipitate forms when protamine sulfate is dropped into citrated plasma. The test is negative in the presence of primary <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span>.</p>
<p>The euglobulin clot lysis test is abnormal in primary <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span> but normal in DIC.</p>
<p>AMICAR must not be used in the presence of DIC without concomitant heparin.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_ef34ef64-9888-434e-a176-3b7d765b6eb8"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">In patients with upper urinary tract <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, AMICAR administration has been known to cause intrarenal obstruction in the form of glomerular capillary <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> or clots in the renal pelvis and ureters. For this reason, AMICAR should not be used in <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> of upper urinary tract origin, unless the possible benefits outweigh the risk.</p>
<p>Subendocardial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span> have been observed in dogs given intravenous infusions of 0.2 times the maximum human therapeutic dose of AMICAR and in monkeys given 8 times the maximum human therapeutic dose of AMICAR.</p>
<p>Fatty degeneration of the myocardium has been reported in dogs given intravenous doses of AMICAR at 0.8 to 3.3 times the maximum human therapeutic dose and in monkeys given intravenous doses of AMICAR at 6 times the maximum human therapeutic dose.</p>
<p>Rarely, skeletal <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> with <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> of muscle fibers has been reported following prolonged administration. Clinical presentation may range from mild <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span> with <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> to a severe <span class="product-label-link" type="condition" conceptid="4102023" conceptname="Proximal myopathy">proximal myopathy</span> with <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span>, and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>. Muscle enzymes, especially creatine phosphokinase (CPK) are elevated. CPK levels should be monitored in patients on long-term therapy. AMICAR administration should be stopped if a rise in CPK is noted. Resolution follows discontinuation of AMICAR; however, the syndrome may recur if AMICAR is restarted.</p>
<p>The possibility of cardiac <span class="product-label-link" type="condition" conceptid="4048093" conceptname="Hamstring injury">muscle damage</span> should also be considered when skeletal <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> occurs. One case of cardiac and <span class="product-label-link" type="condition" conceptid="4104000" conceptname="Lesion of liver">hepatic lesions</span> observed in man has been reported. The patient received 2 g of aminocaproic acid every 6 hours for a total dose of 26 g. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> was due to continued cerebrovascular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>. Necrotic changes in the heart and liver were noted at autopsy.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_cb4594e0-e7fe-4f9d-865a-7b2978388d33"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_e7d77822-dd3d-41a9-9f0e-00e53731eefd"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">AMICAR inhibits both the action of <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> activators and to a lesser degree, plasmin activity. The drug should NOT be administered without a definite diagnosis and/or laboratory finding indicative of hyperfibrinolysis (hyperplasminemia).<span class="Sup">1</span> Inhibition of <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span> by aminocaproic acid may theoretically result in clotting or <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>. However, there is no definite evidence that administration of aminocaproic acid has been responsible for the few reported cases of intravascular clotting which followed this treatment. Rather, it appears that such intravascular clotting was most likely due to the patient's preexisting clinical condition, e.g., the presence of DIC. It has been postulated that extravascular clots formed <span class="Italics">in vivo</span> may not undergo spontaneous lysis as do normal clots.</p>
<p>Reports have appeared in the literature of an increased incidence of certain neurological deficits such as <span class="product-label-link" type="condition" conceptid="4043738" conceptname="Hydrocephalus">hydrocephalus</span>, <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span>, or cerebral <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> associated with the use of antifibrinolytic agents in the treatment of <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span> (SAH). All of these events have also been described as part of the natural course of SAH, or as a consequence of diagnostic procedures such as angiography. Drug relatedness remains unclear.</p>
<p>Aminocaproic acid should not be administered with Factor IX Complex concentrates or Anti-Inhibitor Coagulant concentrates, as the risk of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> may be increased.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_307469ed-52ec-40cd-865f-5fa777740377"></a><a name="section-7.2"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">The use of AMICAR should be accompanied by tests designed to determine the amount of <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span> present. There are presently available: (a) general tests such as those for the determination of the lysis of a clot of blood or plasma; and (b) more specific tests for the study of various phases of the fibrinolytic mechanisms. These latter tests include both semiquantitative and quantitative techniques for the determination of profibrinolysin, fibrinolysin, and antifibrinolysin.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_id_b426e9c5-14f9-4c50-8019-1c03a9c6776e"></a><a name="section-7.3"></a><p></p>
<h2>Drug Laboratory Test Interactions</h2>
<p class="First">Prolongation of the template <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> has been reported during continuous intravenous infusion of AMICAR at dosages exceeding 24 g/day. Platelet function studies in these patients have not demonstrated any significant platelet dysfunction. However, <span class="Italics">in vitro</span> studies have shown that at high concentrations (7.4 mMol/L or 0.97 mg/mL and greater) aminocaproic acid inhibits ADP and collagen-induced platelet aggregation, the release of ATP and serotonin, and the binding of fibrinogen to the platelets in a concentration-response manner. Following a 10 g bolus of AMICAR, transient peak plasma concentrations of 4.6 mMol/L or 0.60 mg/mL have been obtained. The concentration of AMICAR necessary to maintain inhibition of <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span> is 0.99 mMol/L or 0.13 mg/mL. Administration of a 5 g bolus followed by 1 to 1.25 g/hr should achieve and sustain plasma levels of 0.13 mg/mL. Thus, concentrations which have been obtained <span class="Italics">in vivo</span> clinically in patients with normal renal function are considerably lower than the <span class="Italics">in vitro</span> concentrations found to induce abnormalities in platelet function tests. However, higher plasma concentrations of AMICAR may occur in patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_e497fa4a-013c-4ef8-b0da-4791a83b2e3a"></a><a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies in animals to evaluate the carcinogenic potential of AMICAR and studies to evaluate its mutagenic potential have not been conducted. Dietary administration of an equivalent of the maximum human therapeutic dose of AMICAR to rats of both sexes impaired fertility as evidenced by decreased implantations, litter sizes and number of pups born.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_96ceef5c-2761-40c7-a940-ae834bb3abe4"></a><a name="section-7.5"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"><span class="Italics">Pregnancy Category C.</span> Animal reproduction studies have not been conducted with AMICAR. It is also not known whether AMICAR can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. AMICAR should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_0092db08-5c96-4cbb-863e-2db70ea70455"></a><a name="section-7.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when AMICAR is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_39567bb7-2f42-4d35-80cf-16adaa045f4f"></a><a name="section-7.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_27cf4785-e11f-4b42-b077-c1f095495323"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">AMICAR is generally well tolerated. The following adverse experiences have been reported:</p>
<p><span class="Bold">General:</span> <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>:</span> Allergic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>.</p>
<p><span class="Bold">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4124836" conceptname="Peripheral ischemia">peripheral ischemia</span>, <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>.</p>
<p><span class="Bold">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p><span class="Bold">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorder</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="Bold">Musculoskeletal:</span> CPK increased, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> (see <span class="Bold"><a href="#i4i_warnings_id_ef34ef64-9888-434e-a176-3b7d765b6eb8">WARNINGS</a></span>), <span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span>, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>.</p>
<p><span class="Bold">Neurologic:</span> <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">intracranial hypertension</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</p>
<p><span class="Bold">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>.</p>
<p><span class="Bold">Skin:</span> Pruritis, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
<p><span class="Bold">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span>, <span class="product-label-link" type="condition" conceptid="376402" conceptname="Low vision, one eye">vision decreased</span>, watery eyes.</p>
<p><span class="Bold">Urogenital:</span> BUN increased, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>. There have been some reports of dry ejaculation during the period of AMICAR treatment. These have been reported to date only in <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span> patients who received the drug after undergoing dental surgical procedures. However, this symptom resolved in all patients within 24 to 48 hours of completion of therapy.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_b604dc03-5d51-4e46-ba57-8fe9aeb94b89"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">A few cases of acute overdosage with AMICAR administered intravenously have been reported. The effects have ranged from no reaction to transient <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> to severe <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. One patient with a history of <span class="product-label-link" type="condition" conceptid="4116092" conceptname="Intracranial tumor">brain tumor</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> experienced <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> after receiving an 8 gram bolus injection of AMICAR. The single dose of AMICAR causing symptoms of overdosage or considered to be life-threatening is unknown. Patients have tolerated doses as high as 100 grams while <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> has been reported following a dose of 12 grams.</p>
<p>The intravenous and oral LD<span class="Sub">50</span> of AMICAR were 3.0 and 12.0 g/kg, respectively, in the mouse and 3.2 and 16.4 g/kg, respectively, in the rat. An intravenous infusion dose of 2.3 g/kg was lethal in the dog. On intravenous administration, tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic convulsions</span> were observed in dogs and mice.</p>
<p>No treatment for overdosage is known, although evidence exists that AMICAR is removed by hemodialysis and may be removed by peritoneal dialysis. Pharmacokinetic studies have shown that total body clearance of AMICAR is markedly decreased in patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_f76073a6-b892-4788-a5cc-99d965094a58"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">An identical dosage regimen may be followed by administering AMICAR Tablets or AMICAR Oral Solution as follows:</p>
<p>For the treatment of acute <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> syndromes due to elevated fibrinolytic activity, it is suggested that 5 AMICAR 1000 mg Tablets or 10 AMICAR 500 mg Tablets (5 g) or 20 milliliter of AMICAR Oral Solution (5 g) be administered during the first hour of treatment, followed by a continuing rate of 1 AMICAR 1000 mg Tablet or 2 AMICAR 500 mg Tablets (1 g) or 5 milliliter of AMICAR Oral Solution (1.25 g) per hour. This method of treatment would ordinarily be continued for about 8 hours or until the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> situation has been controlled.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_ee28a58f-ebea-457c-aa4e-b02409869603"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">AMICAR<span class="Sup">® </span><br>(aminocaproic acid) </p>
<p><span class="Bold">AMICAR Oral Solution, 0.25 g/mL</span></p>
<p>Each mL of raspberry-flavored oral solution contains 0.25 g/mL of aminocaproic acid. </p>
<p>8 Fl. Oz. (236.5 mL) Bottle – NDC 49411-052-08</p>
<p><span class="Italics">Store at 20°-25°C (68°-77°F)[see USP Controlled Room Temperature];Dispense in Tight Containers; Do Not Freeze.</span></p>
<p><span class="Bold">AMICAR 500 mg Tablets</span></p>
<p>Each round, white tablet, engraved with XP on one side and scored on the other with A to the left of the score and 10 on the right, contains 500 mg of aminocaproic acid. </p>
<p>Bottle of 30 – NDC 49411-050-30</p>
<p><span class="Italics">Store at 20°-25°C (68°-77°F)[see USP Controlled Room Temperature];Dispense in Tight Containers; Do Not Freeze.</span></p>
<p><span class="Bold">AMICAR 1000 mg Tablets</span></p>
<p>Each oblong, white tablet, engraved with XP on one side and scored on the other with A to the left of the score and 20 on the right, contains 1000 mg of aminocaproic acid. </p>
<p>Bottle of 30 – NDC 49411-051-30</p>
<p><span class="Italics">Store at 20°-25°C (68°-77°F)[see USP Controlled Room Temperature];Dispense in Tight Containers; Do Not Freeze.</span></p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_82b28369-38db-4c7c-91a8-3525276adede"></a><a name="section-12"></a><p></p>
<h1>REFERENCE</h1>
<p class="First"><span class="Sup">1</span> Stefanini M, Dameshek W: <span class="Italics">The <span class="product-label-link" type="condition" conceptid="432869" conceptname="Hemorrhagic disorder due to circulating anticoagulants">Hemorrhagic Disorders</span>,</span> Ed. 2, New York, Grune and Stratton; 1962:510-514.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b871fdaf-26de-402b-b6cb-716ab4829681"></a><a name="section-13"></a><p></p>
<p class="First">Marketed by <br><a name="id-1405215907"></a><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2238c70f-b0b5-4755-896b-45b28777b217&amp;name=image-02.jpg"><br>Marietta, GA 30062</p>
<p>Code 909B00<br>Rev. 05/15</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_bd005227-a11d-419b-962a-eeb162b7cda4"></a><a name="section-14"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</h1>
<p class="First">Bottle Label – 8 Fl. Oz. (236.5 mL)<br>NDC 49411-052-08<br><span class="Bold">AMICAR<span class="Sup">®</span></span><br><span class="Bold">Aminocaproic Acid</span><br><span class="Bold">Oral Solution</span><br><span class="Bold">0.25 grams/mL</span><br><span class="Bold">Rx only</span><br>8 Fl. Oz. (236.5 mL)</p>
<div class="Figure">
<a name="id338437212"></a><img alt="Bottle Label – 8 Fl. Oz. (236.5 mL)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2238c70f-b0b5-4755-896b-45b28777b217&amp;name=9ce611a6-1000-4b17-bfe2-3ab2771285ba-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_0c53d211-78f4-44fe-8ae2-77d06ddd817c"></a><a name="section-15"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</h1>
<p class="First">Bottle Label – 500 mg<br>NDC 49411-050-30<br><span class="Bold">500 mg</span><br><span class="Bold">AMICAR<span class="Sup">®</span></span><br><span class="Bold">Aminocaproic Acid</span><br><span class="Bold">Tablets</span><br><span class="Bold">Rx Only</span><br><span class="Bold">30 Tablets </span></p>
<div class="Figure">
<a name="id-1646812951"></a><img alt="Bottle Label-500 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2238c70f-b0b5-4755-896b-45b28777b217&amp;name=9ce611a6-1000-4b17-bfe2-3ab2771285ba-04.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_12ad9c23-a455-4ebf-9396-5c72a31fe6f1"></a><a name="section-16"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</h1>
<p class="First">Bottle Label – 1000 mg<br>NDC 49411-051-30<br><span class="Bold">1000 mg</span><br><span class="Bold">AMICAR<span class="Sup">®</span></span><br><span class="Bold">Aminocaproic Acid</span><br><span class="Bold">Tablets</span><br><span class="Bold">Rx Only</span><br><span class="Bold">30 Tablets</span></p>
<div class="Figure">
<a name="id27536283"></a><img alt="Bottle Label-1000 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2238c70f-b0b5-4755-896b-45b28777b217&amp;name=9ce611a6-1000-4b17-bfe2-3ab2771285ba-05.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMICAR 		
					</strong><br><span class="contentTableReg">aminocaproic acid solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49411-052</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMINOCAPROIC ACID</strong> (AMINOCAPROIC ACID) </td>
<td class="formItem">AMINOCAPROIC ACID</td>
<td class="formItem">0.25 g  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ANHYDROUS CITRIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>RASPBERRY</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">RASPBERRY (RASPBERRY) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49411-052-08</td>
<td class="formItem">236.5 mL in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem">06/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA015230</td>
<td class="formItem">06/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMICAR 		
					</strong><br><span class="contentTableReg">aminocaproic acid tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49411-050</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMINOCAPROIC ACID</strong> (AMINOCAPROIC ACID) </td>
<td class="formItem">AMINOCAPROIC ACID</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (WHITE) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">XP;A;10</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49411-050-30</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem">06/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA015197</td>
<td class="formItem">06/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMICAR 		
					</strong><br><span class="contentTableReg">aminocaproic acid tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49411-051</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMINOCAPROIC ACID</strong> (AMINOCAPROIC ACID) </td>
<td class="formItem">AMINOCAPROIC ACID</td>
<td class="formItem">1000 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (WHITE) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">XP;A;20</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49411-051-30</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem">06/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA015197</td>
<td class="formItem">06/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Clover Pharmaceuticals Corp.
							(078398998)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>bba3bfb1-b56e-4370-8b68-25f18db3fc02</div>
<div>Set id: 2238c70f-b0b5-4755-896b-45b28777b217</div>
<div>Version: 4</div>
<div>Effective Time: 20150611</div>
</div>
</div> <div class="DistributorName">Clover Pharmaceuticals Corp.</div></p>
</body></html>
<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>AMICAR- aminocaproic acid solution </strong><br><strong>AMICAR- aminocaproic acid tablet </strong><br>Clover Pharmaceuticals Corp.<br></p></div>
<h1>
<span class="Bold">AMICAR<span class="Sup">®</span> (aminocaproic acid)</span><br><span class="Bold"> Oral Solution and Tablets</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1ef7238a-b2eb-4e7c-b28f-0284c88fe822"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">R<span class="Sub">x</span> only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_c71a5a0c-5953-4571-9b82-42ab33d68e7b"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">AMICAR (aminocaproic acid) is 6-aminohexanoic acid, which acts as an inhibitor of <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span>.</p>
<p>Its chemical structure is:</p>
<div class="Figure">
<a name="id-145903807"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2238c70f-b0b5-4755-896b-45b28777b217&amp;name=image-01.jpg">
</div>
<p>AMICAR is soluble in water, acid, and alkaline solutions; it is sparingly soluble in methanol and practically insoluble in chloroform.</p>
<p>AMICAR (aminocaproic acid) Oral Solution for oral administration, contains 0.25 g/mL of aminocaproic acid with methylparaben 0.20%, propylparaben 0.05%, edetate disodium 0.30% as preservatives and the following inactive ingredients: sodium saccharin, sorbitol solution, citric acid anhydrous, natural and artificial raspberry flavor and an artificial bitterness modifier.</p>
<p>Each AMICAR (aminocaproic acid) Tablet, for oral administration contains 500 mg or 1000 mg of aminocaproic acid and the following inactive ingredients: povidone, crospovidone, stearic acid, and magnesium stearate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_f1f24186-1617-4e70-b83a-675df4f89101"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">The <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span>-inhibitory effects of AMICAR appear to be exerted principally via inhibition of <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> activators and to a lesser degree through antiplasmin activity.</p>
<p>In adults, oral absorption appears to be a zero-order process with an absorption rate of 5.2 g/hr. The mean lag time in absorption is 10 minutes. After a single oral dose of 5 g, absorption was complete (F=1). Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.</p>
<p>After oral administration, the apparent volume of distribution was estimated to be 23.1 ± 6.6 L (mean ± SD). Correspondingly, the volume of distribution after intravenous administration has been reported to be 30.0 ± 8.2 L. After prolonged administration, AMICAR has been found to distribute throughout extravascular and intravascular compartments of the body, penetrating human red blood cells as well as other tissue cells.</p>
<p>Renal excretion is the primary route of elimination. Sixty-five percent of the dose is recovered in the urine as unchanged drug and 11% of the dose appears as the metabolite adipic acid. Renal clearance (116 mL/min) approximates endogenous creatinine clearance. The total body clearance is 169 mL/min. The terminal elimination half-life for AMICAR is approximately 2 hours.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_74156542-c557-483e-9acb-51dae4a4e447"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">AMICAR is useful in enhancing hemostasis when <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span> contributes to <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required.</p>
<p>Fibrinolytic <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (accompanying <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>); acute and life-threatening <span class="product-label-link" type="condition" conceptid="198488" conceptname="Placental abruption">abruptio placentae</span>; <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span>; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix.</p>
<p>Urinary <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span>, usually a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> associated with surgical <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> (following prostatectomy and nephrectomy) or nonsurgical <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> (accompanying polycystic or neoplastic diseases of the genitourinary system). (See <span class="Bold"><a href="#i4i_warnings_id_ef34ef64-9888-434e-a176-3b7d765b6eb8">WARNINGS</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_3faf40ed-904d-4be9-bb7e-81d62840ba00"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">AMICAR should not be used when there is evidence of an active intravascular clotting process.</p>
<p>When there is uncertainty as to whether the cause of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is primary <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span> or <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span> (DIC), this distinction must be made before administering AMICAR.</p>
<p>The following tests can be applied to differentiate the two conditions:</p>
<p>Platelet count is usually decreased in DIC but normal in primary <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span>.</p>
<p>Protamine paracoagulation test is positive in DIC; a precipitate forms when protamine sulfate is dropped into citrated plasma. The test is negative in the presence of primary <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span>.</p>
<p>The euglobulin clot lysis test is abnormal in primary <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span> but normal in DIC.</p>
<p>AMICAR must not be used in the presence of DIC without concomitant heparin.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_ef34ef64-9888-434e-a176-3b7d765b6eb8"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">In patients with upper urinary tract <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, AMICAR administration has been known to cause intrarenal obstruction in the form of glomerular capillary <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> or clots in the renal pelvis and ureters. For this reason, AMICAR should not be used in <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> of upper urinary tract origin, unless the possible benefits outweigh the risk.</p>
<p>Subendocardial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span> have been observed in dogs given intravenous infusions of 0.2 times the maximum human therapeutic dose of AMICAR and in monkeys given 8 times the maximum human therapeutic dose of AMICAR.</p>
<p>Fatty degeneration of the myocardium has been reported in dogs given intravenous doses of AMICAR at 0.8 to 3.3 times the maximum human therapeutic dose and in monkeys given intravenous doses of AMICAR at 6 times the maximum human therapeutic dose.</p>
<p>Rarely, skeletal <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> with <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> of muscle fibers has been reported following prolonged administration. Clinical presentation may range from mild <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span> with <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> to a severe <span class="product-label-link" type="condition" conceptid="4102023" conceptname="Proximal myopathy">proximal myopathy</span> with <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span>, and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>. Muscle enzymes, especially creatine phosphokinase (CPK) are elevated. CPK levels should be monitored in patients on long-term therapy. AMICAR administration should be stopped if a rise in CPK is noted. Resolution follows discontinuation of AMICAR; however, the syndrome may recur if AMICAR is restarted.</p>
<p>The possibility of cardiac <span class="product-label-link" type="condition" conceptid="4048093" conceptname="Hamstring injury">muscle damage</span> should also be considered when skeletal <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> occurs. One case of cardiac and <span class="product-label-link" type="condition" conceptid="4104000" conceptname="Lesion of liver">hepatic lesions</span> observed in man has been reported. The patient received 2 g of aminocaproic acid every 6 hours for a total dose of 26 g. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> was due to continued cerebrovascular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>. Necrotic changes in the heart and liver were noted at autopsy.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_cb4594e0-e7fe-4f9d-865a-7b2978388d33"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_e7d77822-dd3d-41a9-9f0e-00e53731eefd"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">AMICAR inhibits both the action of <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> activators and to a lesser degree, plasmin activity. The drug should NOT be administered without a definite diagnosis and/or laboratory finding indicative of hyperfibrinolysis (hyperplasminemia).<span class="Sup">1</span> Inhibition of <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span> by aminocaproic acid may theoretically result in clotting or <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>. However, there is no definite evidence that administration of aminocaproic acid has been responsible for the few reported cases of intravascular clotting which followed this treatment. Rather, it appears that such intravascular clotting was most likely due to the patient's preexisting clinical condition, e.g., the presence of DIC. It has been postulated that extravascular clots formed <span class="Italics">in vivo</span> may not undergo spontaneous lysis as do normal clots.</p>
<p>Reports have appeared in the literature of an increased incidence of certain neurological deficits such as <span class="product-label-link" type="condition" conceptid="4043738" conceptname="Hydrocephalus">hydrocephalus</span>, <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span>, or cerebral <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> associated with the use of antifibrinolytic agents in the treatment of <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span> (SAH). All of these events have also been described as part of the natural course of SAH, or as a consequence of diagnostic procedures such as angiography. Drug relatedness remains unclear.</p>
<p>Aminocaproic acid should not be administered with Factor IX Complex concentrates or Anti-Inhibitor Coagulant concentrates, as the risk of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> may be increased.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_307469ed-52ec-40cd-865f-5fa777740377"></a><a name="section-7.2"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">The use of AMICAR should be accompanied by tests designed to determine the amount of <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span> present. There are presently available: (a) general tests such as those for the determination of the lysis of a clot of blood or plasma; and (b) more specific tests for the study of various phases of the fibrinolytic mechanisms. These latter tests include both semiquantitative and quantitative techniques for the determination of profibrinolysin, fibrinolysin, and antifibrinolysin.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_id_b426e9c5-14f9-4c50-8019-1c03a9c6776e"></a><a name="section-7.3"></a><p></p>
<h2>Drug Laboratory Test Interactions</h2>
<p class="First">Prolongation of the template <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> has been reported during continuous intravenous infusion of AMICAR at dosages exceeding 24 g/day. Platelet function studies in these patients have not demonstrated any significant platelet dysfunction. However, <span class="Italics">in vitro</span> studies have shown that at high concentrations (7.4 mMol/L or 0.97 mg/mL and greater) aminocaproic acid inhibits ADP and collagen-induced platelet aggregation, the release of ATP and serotonin, and the binding of fibrinogen to the platelets in a concentration-response manner. Following a 10 g bolus of AMICAR, transient peak plasma concentrations of 4.6 mMol/L or 0.60 mg/mL have been obtained. The concentration of AMICAR necessary to maintain inhibition of <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span> is 0.99 mMol/L or 0.13 mg/mL. Administration of a 5 g bolus followed by 1 to 1.25 g/hr should achieve and sustain plasma levels of 0.13 mg/mL. Thus, concentrations which have been obtained <span class="Italics">in vivo</span> clinically in patients with normal renal function are considerably lower than the <span class="Italics">in vitro</span> concentrations found to induce abnormalities in platelet function tests. However, higher plasma concentrations of AMICAR may occur in patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_e497fa4a-013c-4ef8-b0da-4791a83b2e3a"></a><a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies in animals to evaluate the carcinogenic potential of AMICAR and studies to evaluate its mutagenic potential have not been conducted. Dietary administration of an equivalent of the maximum human therapeutic dose of AMICAR to rats of both sexes impaired fertility as evidenced by decreased implantations, litter sizes and number of pups born.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_96ceef5c-2761-40c7-a940-ae834bb3abe4"></a><a name="section-7.5"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"><span class="Italics">Pregnancy Category C.</span> Animal reproduction studies have not been conducted with AMICAR. It is also not known whether AMICAR can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. AMICAR should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_0092db08-5c96-4cbb-863e-2db70ea70455"></a><a name="section-7.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when AMICAR is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_39567bb7-2f42-4d35-80cf-16adaa045f4f"></a><a name="section-7.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_27cf4785-e11f-4b42-b077-c1f095495323"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">AMICAR is generally well tolerated. The following adverse experiences have been reported:</p>
<p><span class="Bold">General:</span> <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>:</span> Allergic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>.</p>
<p><span class="Bold">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4124836" conceptname="Peripheral ischemia">peripheral ischemia</span>, <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>.</p>
<p><span class="Bold">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p><span class="Bold">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorder</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="Bold">Musculoskeletal:</span> CPK increased, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> (see <span class="Bold"><a href="#i4i_warnings_id_ef34ef64-9888-434e-a176-3b7d765b6eb8">WARNINGS</a></span>), <span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span>, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>.</p>
<p><span class="Bold">Neurologic:</span> <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">intracranial hypertension</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</p>
<p><span class="Bold">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>.</p>
<p><span class="Bold">Skin:</span> Pruritis, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
<p><span class="Bold">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span>, <span class="product-label-link" type="condition" conceptid="376402" conceptname="Low vision, one eye">vision decreased</span>, watery eyes.</p>
<p><span class="Bold">Urogenital:</span> BUN increased, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>. There have been some reports of dry ejaculation during the period of AMICAR treatment. These have been reported to date only in <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span> patients who received the drug after undergoing dental surgical procedures. However, this symptom resolved in all patients within 24 to 48 hours of completion of therapy.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_b604dc03-5d51-4e46-ba57-8fe9aeb94b89"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">A few cases of acute overdosage with AMICAR administered intravenously have been reported. The effects have ranged from no reaction to transient <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> to severe <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. One patient with a history of <span class="product-label-link" type="condition" conceptid="4116092" conceptname="Intracranial tumor">brain tumor</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> experienced <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> after receiving an 8 gram bolus injection of AMICAR. The single dose of AMICAR causing symptoms of overdosage or considered to be life-threatening is unknown. Patients have tolerated doses as high as 100 grams while <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> has been reported following a dose of 12 grams.</p>
<p>The intravenous and oral LD<span class="Sub">50</span> of AMICAR were 3.0 and 12.0 g/kg, respectively, in the mouse and 3.2 and 16.4 g/kg, respectively, in the rat. An intravenous infusion dose of 2.3 g/kg was lethal in the dog. On intravenous administration, tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic convulsions</span> were observed in dogs and mice.</p>
<p>No treatment for overdosage is known, although evidence exists that AMICAR is removed by hemodialysis and may be removed by peritoneal dialysis. Pharmacokinetic studies have shown that total body clearance of AMICAR is markedly decreased in patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_f76073a6-b892-4788-a5cc-99d965094a58"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">An identical dosage regimen may be followed by administering AMICAR Tablets or AMICAR Oral Solution as follows:</p>
<p>For the treatment of acute <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> syndromes due to elevated fibrinolytic activity, it is suggested that 5 AMICAR 1000 mg Tablets or 10 AMICAR 500 mg Tablets (5 g) or 20 milliliter of AMICAR Oral Solution (5 g) be administered during the first hour of treatment, followed by a continuing rate of 1 AMICAR 1000 mg Tablet or 2 AMICAR 500 mg Tablets (1 g) or 5 milliliter of AMICAR Oral Solution (1.25 g) per hour. This method of treatment would ordinarily be continued for about 8 hours or until the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> situation has been controlled.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_ee28a58f-ebea-457c-aa4e-b02409869603"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">AMICAR<span class="Sup">® </span><br>(aminocaproic acid) </p>
<p><span class="Bold">AMICAR Oral Solution, 0.25 g/mL</span></p>
<p>Each mL of raspberry-flavored oral solution contains 0.25 g/mL of aminocaproic acid. </p>
<p>8 Fl. Oz. (236.5 mL) Bottle – NDC 49411-052-08</p>
<p><span class="Italics">Store at 20°-25°C (68°-77°F)[see USP Controlled Room Temperature];Dispense in Tight Containers; Do Not Freeze.</span></p>
<p><span class="Bold">AMICAR 500 mg Tablets</span></p>
<p>Each round, white tablet, engraved with XP on one side and scored on the other with A to the left of the score and 10 on the right, contains 500 mg of aminocaproic acid. </p>
<p>Bottle of 30 – NDC 49411-050-30</p>
<p><span class="Italics">Store at 20°-25°C (68°-77°F)[see USP Controlled Room Temperature];Dispense in Tight Containers; Do Not Freeze.</span></p>
<p><span class="Bold">AMICAR 1000 mg Tablets</span></p>
<p>Each oblong, white tablet, engraved with XP on one side and scored on the other with A to the left of the score and 20 on the right, contains 1000 mg of aminocaproic acid. </p>
<p>Bottle of 30 – NDC 49411-051-30</p>
<p><span class="Italics">Store at 20°-25°C (68°-77°F)[see USP Controlled Room Temperature];Dispense in Tight Containers; Do Not Freeze.</span></p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_82b28369-38db-4c7c-91a8-3525276adede"></a><a name="section-12"></a><p></p>
<h1>REFERENCE</h1>
<p class="First"><span class="Sup">1</span> Stefanini M, Dameshek W: <span class="Italics">The <span class="product-label-link" type="condition" conceptid="432869" conceptname="Hemorrhagic disorder due to circulating anticoagulants">Hemorrhagic Disorders</span>,</span> Ed. 2, New York, Grune and Stratton; 1962:510-514.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b871fdaf-26de-402b-b6cb-716ab4829681"></a><a name="section-13"></a><p></p>
<p class="First">Marketed by <br><a name="id-1405215907"></a><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2238c70f-b0b5-4755-896b-45b28777b217&amp;name=image-02.jpg"><br>Marietta, GA 30062</p>
<p>Code 909B00<br>Rev. 05/15</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_bd005227-a11d-419b-962a-eeb162b7cda4"></a><a name="section-14"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</h1>
<p class="First">Bottle Label – 8 Fl. Oz. (236.5 mL)<br>NDC 49411-052-08<br><span class="Bold">AMICAR<span class="Sup">®</span></span><br><span class="Bold">Aminocaproic Acid</span><br><span class="Bold">Oral Solution</span><br><span class="Bold">0.25 grams/mL</span><br><span class="Bold">Rx only</span><br>8 Fl. Oz. (236.5 mL)</p>
<div class="Figure">
<a name="id338437212"></a><img alt="Bottle Label – 8 Fl. Oz. (236.5 mL)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2238c70f-b0b5-4755-896b-45b28777b217&amp;name=9ce611a6-1000-4b17-bfe2-3ab2771285ba-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_0c53d211-78f4-44fe-8ae2-77d06ddd817c"></a><a name="section-15"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</h1>
<p class="First">Bottle Label – 500 mg<br>NDC 49411-050-30<br><span class="Bold">500 mg</span><br><span class="Bold">AMICAR<span class="Sup">®</span></span><br><span class="Bold">Aminocaproic Acid</span><br><span class="Bold">Tablets</span><br><span class="Bold">Rx Only</span><br><span class="Bold">30 Tablets </span></p>
<div class="Figure">
<a name="id-1646812951"></a><img alt="Bottle Label-500 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2238c70f-b0b5-4755-896b-45b28777b217&amp;name=9ce611a6-1000-4b17-bfe2-3ab2771285ba-04.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_12ad9c23-a455-4ebf-9396-5c72a31fe6f1"></a><a name="section-16"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</h1>
<p class="First">Bottle Label – 1000 mg<br>NDC 49411-051-30<br><span class="Bold">1000 mg</span><br><span class="Bold">AMICAR<span class="Sup">®</span></span><br><span class="Bold">Aminocaproic Acid</span><br><span class="Bold">Tablets</span><br><span class="Bold">Rx Only</span><br><span class="Bold">30 Tablets</span></p>
<div class="Figure">
<a name="id27536283"></a><img alt="Bottle Label-1000 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2238c70f-b0b5-4755-896b-45b28777b217&amp;name=9ce611a6-1000-4b17-bfe2-3ab2771285ba-05.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMICAR 		
					</strong><br><span class="contentTableReg">aminocaproic acid solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49411-052</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMINOCAPROIC ACID</strong> (AMINOCAPROIC ACID) </td>
<td class="formItem">AMINOCAPROIC ACID</td>
<td class="formItem">0.25 g  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ANHYDROUS CITRIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>RASPBERRY</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">RASPBERRY (RASPBERRY) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49411-052-08</td>
<td class="formItem">236.5 mL in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem">06/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA015230</td>
<td class="formItem">06/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMICAR 		
					</strong><br><span class="contentTableReg">aminocaproic acid tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49411-050</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMINOCAPROIC ACID</strong> (AMINOCAPROIC ACID) </td>
<td class="formItem">AMINOCAPROIC ACID</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (WHITE) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">XP;A;10</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49411-050-30</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem">06/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA015197</td>
<td class="formItem">06/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMICAR 		
					</strong><br><span class="contentTableReg">aminocaproic acid tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49411-051</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMINOCAPROIC ACID</strong> (AMINOCAPROIC ACID) </td>
<td class="formItem">AMINOCAPROIC ACID</td>
<td class="formItem">1000 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (WHITE) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">XP;A;20</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49411-051-30</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem">06/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA015197</td>
<td class="formItem">06/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Clover Pharmaceuticals Corp.
							(078398998)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>bba3bfb1-b56e-4370-8b68-25f18db3fc02</div>
<div>Set id: 2238c70f-b0b5-4755-896b-45b28777b217</div>
<div>Version: 4</div>
<div>Effective Time: 20150611</div>
</div>
</div> <div class="DistributorName">Clover Pharmaceuticals Corp.</div></p>
</body></html>
<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>AMICAR- aminocaproic acid solution </strong><br><strong>AMICAR- aminocaproic acid tablet </strong><br>Clover Pharmaceuticals Corp.<br></p></div>
<h1>
<span class="Bold">AMICAR<span class="Sup">®</span> (aminocaproic acid)</span><br><span class="Bold"> Oral Solution and Tablets</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1ef7238a-b2eb-4e7c-b28f-0284c88fe822"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">R<span class="Sub">x</span> only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_c71a5a0c-5953-4571-9b82-42ab33d68e7b"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">AMICAR (aminocaproic acid) is 6-aminohexanoic acid, which acts as an inhibitor of <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span>.</p>
<p>Its chemical structure is:</p>
<div class="Figure">
<a name="id-145903807"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2238c70f-b0b5-4755-896b-45b28777b217&amp;name=image-01.jpg">
</div>
<p>AMICAR is soluble in water, acid, and alkaline solutions; it is sparingly soluble in methanol and practically insoluble in chloroform.</p>
<p>AMICAR (aminocaproic acid) Oral Solution for oral administration, contains 0.25 g/mL of aminocaproic acid with methylparaben 0.20%, propylparaben 0.05%, edetate disodium 0.30% as preservatives and the following inactive ingredients: sodium saccharin, sorbitol solution, citric acid anhydrous, natural and artificial raspberry flavor and an artificial bitterness modifier.</p>
<p>Each AMICAR (aminocaproic acid) Tablet, for oral administration contains 500 mg or 1000 mg of aminocaproic acid and the following inactive ingredients: povidone, crospovidone, stearic acid, and magnesium stearate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_f1f24186-1617-4e70-b83a-675df4f89101"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">The <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span>-inhibitory effects of AMICAR appear to be exerted principally via inhibition of <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> activators and to a lesser degree through antiplasmin activity.</p>
<p>In adults, oral absorption appears to be a zero-order process with an absorption rate of 5.2 g/hr. The mean lag time in absorption is 10 minutes. After a single oral dose of 5 g, absorption was complete (F=1). Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.</p>
<p>After oral administration, the apparent volume of distribution was estimated to be 23.1 ± 6.6 L (mean ± SD). Correspondingly, the volume of distribution after intravenous administration has been reported to be 30.0 ± 8.2 L. After prolonged administration, AMICAR has been found to distribute throughout extravascular and intravascular compartments of the body, penetrating human red blood cells as well as other tissue cells.</p>
<p>Renal excretion is the primary route of elimination. Sixty-five percent of the dose is recovered in the urine as unchanged drug and 11% of the dose appears as the metabolite adipic acid. Renal clearance (116 mL/min) approximates endogenous creatinine clearance. The total body clearance is 169 mL/min. The terminal elimination half-life for AMICAR is approximately 2 hours.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_74156542-c557-483e-9acb-51dae4a4e447"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">AMICAR is useful in enhancing hemostasis when <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span> contributes to <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required.</p>
<p>Fibrinolytic <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (accompanying <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>); acute and life-threatening <span class="product-label-link" type="condition" conceptid="198488" conceptname="Placental abruption">abruptio placentae</span>; <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span>; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix.</p>
<p>Urinary <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span>, usually a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> associated with surgical <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> (following prostatectomy and nephrectomy) or nonsurgical <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> (accompanying polycystic or neoplastic diseases of the genitourinary system). (See <span class="Bold"><a href="#i4i_warnings_id_ef34ef64-9888-434e-a176-3b7d765b6eb8">WARNINGS</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_3faf40ed-904d-4be9-bb7e-81d62840ba00"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">AMICAR should not be used when there is evidence of an active intravascular clotting process.</p>
<p>When there is uncertainty as to whether the cause of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is primary <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span> or <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span> (DIC), this distinction must be made before administering AMICAR.</p>
<p>The following tests can be applied to differentiate the two conditions:</p>
<p>Platelet count is usually decreased in DIC but normal in primary <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span>.</p>
<p>Protamine paracoagulation test is positive in DIC; a precipitate forms when protamine sulfate is dropped into citrated plasma. The test is negative in the presence of primary <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span>.</p>
<p>The euglobulin clot lysis test is abnormal in primary <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span> but normal in DIC.</p>
<p>AMICAR must not be used in the presence of DIC without concomitant heparin.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_ef34ef64-9888-434e-a176-3b7d765b6eb8"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">In patients with upper urinary tract <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, AMICAR administration has been known to cause intrarenal obstruction in the form of glomerular capillary <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> or clots in the renal pelvis and ureters. For this reason, AMICAR should not be used in <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> of upper urinary tract origin, unless the possible benefits outweigh the risk.</p>
<p>Subendocardial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span> have been observed in dogs given intravenous infusions of 0.2 times the maximum human therapeutic dose of AMICAR and in monkeys given 8 times the maximum human therapeutic dose of AMICAR.</p>
<p>Fatty degeneration of the myocardium has been reported in dogs given intravenous doses of AMICAR at 0.8 to 3.3 times the maximum human therapeutic dose and in monkeys given intravenous doses of AMICAR at 6 times the maximum human therapeutic dose.</p>
<p>Rarely, skeletal <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> with <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> of muscle fibers has been reported following prolonged administration. Clinical presentation may range from mild <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span> with <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> to a severe <span class="product-label-link" type="condition" conceptid="4102023" conceptname="Proximal myopathy">proximal myopathy</span> with <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span>, and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>. Muscle enzymes, especially creatine phosphokinase (CPK) are elevated. CPK levels should be monitored in patients on long-term therapy. AMICAR administration should be stopped if a rise in CPK is noted. Resolution follows discontinuation of AMICAR; however, the syndrome may recur if AMICAR is restarted.</p>
<p>The possibility of cardiac <span class="product-label-link" type="condition" conceptid="4048093" conceptname="Hamstring injury">muscle damage</span> should also be considered when skeletal <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> occurs. One case of cardiac and <span class="product-label-link" type="condition" conceptid="4104000" conceptname="Lesion of liver">hepatic lesions</span> observed in man has been reported. The patient received 2 g of aminocaproic acid every 6 hours for a total dose of 26 g. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> was due to continued cerebrovascular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>. Necrotic changes in the heart and liver were noted at autopsy.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_cb4594e0-e7fe-4f9d-865a-7b2978388d33"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_e7d77822-dd3d-41a9-9f0e-00e53731eefd"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">AMICAR inhibits both the action of <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> activators and to a lesser degree, plasmin activity. The drug should NOT be administered without a definite diagnosis and/or laboratory finding indicative of hyperfibrinolysis (hyperplasminemia).<span class="Sup">1</span> Inhibition of <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span> by aminocaproic acid may theoretically result in clotting or <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>. However, there is no definite evidence that administration of aminocaproic acid has been responsible for the few reported cases of intravascular clotting which followed this treatment. Rather, it appears that such intravascular clotting was most likely due to the patient's preexisting clinical condition, e.g., the presence of DIC. It has been postulated that extravascular clots formed <span class="Italics">in vivo</span> may not undergo spontaneous lysis as do normal clots.</p>
<p>Reports have appeared in the literature of an increased incidence of certain neurological deficits such as <span class="product-label-link" type="condition" conceptid="4043738" conceptname="Hydrocephalus">hydrocephalus</span>, <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span>, or cerebral <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> associated with the use of antifibrinolytic agents in the treatment of <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span> (SAH). All of these events have also been described as part of the natural course of SAH, or as a consequence of diagnostic procedures such as angiography. Drug relatedness remains unclear.</p>
<p>Aminocaproic acid should not be administered with Factor IX Complex concentrates or Anti-Inhibitor Coagulant concentrates, as the risk of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> may be increased.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_307469ed-52ec-40cd-865f-5fa777740377"></a><a name="section-7.2"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">The use of AMICAR should be accompanied by tests designed to determine the amount of <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span> present. There are presently available: (a) general tests such as those for the determination of the lysis of a clot of blood or plasma; and (b) more specific tests for the study of various phases of the fibrinolytic mechanisms. These latter tests include both semiquantitative and quantitative techniques for the determination of profibrinolysin, fibrinolysin, and antifibrinolysin.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_id_b426e9c5-14f9-4c50-8019-1c03a9c6776e"></a><a name="section-7.3"></a><p></p>
<h2>Drug Laboratory Test Interactions</h2>
<p class="First">Prolongation of the template <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> has been reported during continuous intravenous infusion of AMICAR at dosages exceeding 24 g/day. Platelet function studies in these patients have not demonstrated any significant platelet dysfunction. However, <span class="Italics">in vitro</span> studies have shown that at high concentrations (7.4 mMol/L or 0.97 mg/mL and greater) aminocaproic acid inhibits ADP and collagen-induced platelet aggregation, the release of ATP and serotonin, and the binding of fibrinogen to the platelets in a concentration-response manner. Following a 10 g bolus of AMICAR, transient peak plasma concentrations of 4.6 mMol/L or 0.60 mg/mL have been obtained. The concentration of AMICAR necessary to maintain inhibition of <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span> is 0.99 mMol/L or 0.13 mg/mL. Administration of a 5 g bolus followed by 1 to 1.25 g/hr should achieve and sustain plasma levels of 0.13 mg/mL. Thus, concentrations which have been obtained <span class="Italics">in vivo</span> clinically in patients with normal renal function are considerably lower than the <span class="Italics">in vitro</span> concentrations found to induce abnormalities in platelet function tests. However, higher plasma concentrations of AMICAR may occur in patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_e497fa4a-013c-4ef8-b0da-4791a83b2e3a"></a><a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies in animals to evaluate the carcinogenic potential of AMICAR and studies to evaluate its mutagenic potential have not been conducted. Dietary administration of an equivalent of the maximum human therapeutic dose of AMICAR to rats of both sexes impaired fertility as evidenced by decreased implantations, litter sizes and number of pups born.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_96ceef5c-2761-40c7-a940-ae834bb3abe4"></a><a name="section-7.5"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"><span class="Italics">Pregnancy Category C.</span> Animal reproduction studies have not been conducted with AMICAR. It is also not known whether AMICAR can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. AMICAR should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_0092db08-5c96-4cbb-863e-2db70ea70455"></a><a name="section-7.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when AMICAR is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_39567bb7-2f42-4d35-80cf-16adaa045f4f"></a><a name="section-7.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_27cf4785-e11f-4b42-b077-c1f095495323"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">AMICAR is generally well tolerated. The following adverse experiences have been reported:</p>
<p><span class="Bold">General:</span> <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>:</span> Allergic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>.</p>
<p><span class="Bold">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4124836" conceptname="Peripheral ischemia">peripheral ischemia</span>, <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>.</p>
<p><span class="Bold">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p><span class="Bold">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorder</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="Bold">Musculoskeletal:</span> CPK increased, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> (see <span class="Bold"><a href="#i4i_warnings_id_ef34ef64-9888-434e-a176-3b7d765b6eb8">WARNINGS</a></span>), <span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span>, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>.</p>
<p><span class="Bold">Neurologic:</span> <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">intracranial hypertension</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</p>
<p><span class="Bold">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>.</p>
<p><span class="Bold">Skin:</span> Pruritis, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
<p><span class="Bold">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span>, <span class="product-label-link" type="condition" conceptid="376402" conceptname="Low vision, one eye">vision decreased</span>, watery eyes.</p>
<p><span class="Bold">Urogenital:</span> BUN increased, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>. There have been some reports of dry ejaculation during the period of AMICAR treatment. These have been reported to date only in <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span> patients who received the drug after undergoing dental surgical procedures. However, this symptom resolved in all patients within 24 to 48 hours of completion of therapy.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_b604dc03-5d51-4e46-ba57-8fe9aeb94b89"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">A few cases of acute overdosage with AMICAR administered intravenously have been reported. The effects have ranged from no reaction to transient <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> to severe <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. One patient with a history of <span class="product-label-link" type="condition" conceptid="4116092" conceptname="Intracranial tumor">brain tumor</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> experienced <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> after receiving an 8 gram bolus injection of AMICAR. The single dose of AMICAR causing symptoms of overdosage or considered to be life-threatening is unknown. Patients have tolerated doses as high as 100 grams while <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> has been reported following a dose of 12 grams.</p>
<p>The intravenous and oral LD<span class="Sub">50</span> of AMICAR were 3.0 and 12.0 g/kg, respectively, in the mouse and 3.2 and 16.4 g/kg, respectively, in the rat. An intravenous infusion dose of 2.3 g/kg was lethal in the dog. On intravenous administration, tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic convulsions</span> were observed in dogs and mice.</p>
<p>No treatment for overdosage is known, although evidence exists that AMICAR is removed by hemodialysis and may be removed by peritoneal dialysis. Pharmacokinetic studies have shown that total body clearance of AMICAR is markedly decreased in patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_f76073a6-b892-4788-a5cc-99d965094a58"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">An identical dosage regimen may be followed by administering AMICAR Tablets or AMICAR Oral Solution as follows:</p>
<p>For the treatment of acute <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> syndromes due to elevated fibrinolytic activity, it is suggested that 5 AMICAR 1000 mg Tablets or 10 AMICAR 500 mg Tablets (5 g) or 20 milliliter of AMICAR Oral Solution (5 g) be administered during the first hour of treatment, followed by a continuing rate of 1 AMICAR 1000 mg Tablet or 2 AMICAR 500 mg Tablets (1 g) or 5 milliliter of AMICAR Oral Solution (1.25 g) per hour. This method of treatment would ordinarily be continued for about 8 hours or until the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> situation has been controlled.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_ee28a58f-ebea-457c-aa4e-b02409869603"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">AMICAR<span class="Sup">® </span><br>(aminocaproic acid) </p>
<p><span class="Bold">AMICAR Oral Solution, 0.25 g/mL</span></p>
<p>Each mL of raspberry-flavored oral solution contains 0.25 g/mL of aminocaproic acid. </p>
<p>8 Fl. Oz. (236.5 mL) Bottle – NDC 49411-052-08</p>
<p><span class="Italics">Store at 20°-25°C (68°-77°F)[see USP Controlled Room Temperature];Dispense in Tight Containers; Do Not Freeze.</span></p>
<p><span class="Bold">AMICAR 500 mg Tablets</span></p>
<p>Each round, white tablet, engraved with XP on one side and scored on the other with A to the left of the score and 10 on the right, contains 500 mg of aminocaproic acid. </p>
<p>Bottle of 30 – NDC 49411-050-30</p>
<p><span class="Italics">Store at 20°-25°C (68°-77°F)[see USP Controlled Room Temperature];Dispense in Tight Containers; Do Not Freeze.</span></p>
<p><span class="Bold">AMICAR 1000 mg Tablets</span></p>
<p>Each oblong, white tablet, engraved with XP on one side and scored on the other with A to the left of the score and 20 on the right, contains 1000 mg of aminocaproic acid. </p>
<p>Bottle of 30 – NDC 49411-051-30</p>
<p><span class="Italics">Store at 20°-25°C (68°-77°F)[see USP Controlled Room Temperature];Dispense in Tight Containers; Do Not Freeze.</span></p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_82b28369-38db-4c7c-91a8-3525276adede"></a><a name="section-12"></a><p></p>
<h1>REFERENCE</h1>
<p class="First"><span class="Sup">1</span> Stefanini M, Dameshek W: <span class="Italics">The <span class="product-label-link" type="condition" conceptid="432869" conceptname="Hemorrhagic disorder due to circulating anticoagulants">Hemorrhagic Disorders</span>,</span> Ed. 2, New York, Grune and Stratton; 1962:510-514.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b871fdaf-26de-402b-b6cb-716ab4829681"></a><a name="section-13"></a><p></p>
<p class="First">Marketed by <br><a name="id-1405215907"></a><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2238c70f-b0b5-4755-896b-45b28777b217&amp;name=image-02.jpg"><br>Marietta, GA 30062</p>
<p>Code 909B00<br>Rev. 05/15</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_bd005227-a11d-419b-962a-eeb162b7cda4"></a><a name="section-14"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</h1>
<p class="First">Bottle Label – 8 Fl. Oz. (236.5 mL)<br>NDC 49411-052-08<br><span class="Bold">AMICAR<span class="Sup">®</span></span><br><span class="Bold">Aminocaproic Acid</span><br><span class="Bold">Oral Solution</span><br><span class="Bold">0.25 grams/mL</span><br><span class="Bold">Rx only</span><br>8 Fl. Oz. (236.5 mL)</p>
<div class="Figure">
<a name="id338437212"></a><img alt="Bottle Label – 8 Fl. Oz. (236.5 mL)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2238c70f-b0b5-4755-896b-45b28777b217&amp;name=9ce611a6-1000-4b17-bfe2-3ab2771285ba-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_0c53d211-78f4-44fe-8ae2-77d06ddd817c"></a><a name="section-15"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</h1>
<p class="First">Bottle Label – 500 mg<br>NDC 49411-050-30<br><span class="Bold">500 mg</span><br><span class="Bold">AMICAR<span class="Sup">®</span></span><br><span class="Bold">Aminocaproic Acid</span><br><span class="Bold">Tablets</span><br><span class="Bold">Rx Only</span><br><span class="Bold">30 Tablets </span></p>
<div class="Figure">
<a name="id-1646812951"></a><img alt="Bottle Label-500 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2238c70f-b0b5-4755-896b-45b28777b217&amp;name=9ce611a6-1000-4b17-bfe2-3ab2771285ba-04.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_12ad9c23-a455-4ebf-9396-5c72a31fe6f1"></a><a name="section-16"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</h1>
<p class="First">Bottle Label – 1000 mg<br>NDC 49411-051-30<br><span class="Bold">1000 mg</span><br><span class="Bold">AMICAR<span class="Sup">®</span></span><br><span class="Bold">Aminocaproic Acid</span><br><span class="Bold">Tablets</span><br><span class="Bold">Rx Only</span><br><span class="Bold">30 Tablets</span></p>
<div class="Figure">
<a name="id27536283"></a><img alt="Bottle Label-1000 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2238c70f-b0b5-4755-896b-45b28777b217&amp;name=9ce611a6-1000-4b17-bfe2-3ab2771285ba-05.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMICAR 		
					</strong><br><span class="contentTableReg">aminocaproic acid solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49411-052</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMINOCAPROIC ACID</strong> (AMINOCAPROIC ACID) </td>
<td class="formItem">AMINOCAPROIC ACID</td>
<td class="formItem">0.25 g  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ANHYDROUS CITRIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>RASPBERRY</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">RASPBERRY (RASPBERRY) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49411-052-08</td>
<td class="formItem">236.5 mL in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem">06/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA015230</td>
<td class="formItem">06/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMICAR 		
					</strong><br><span class="contentTableReg">aminocaproic acid tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49411-050</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMINOCAPROIC ACID</strong> (AMINOCAPROIC ACID) </td>
<td class="formItem">AMINOCAPROIC ACID</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (WHITE) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">XP;A;10</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49411-050-30</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem">06/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA015197</td>
<td class="formItem">06/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMICAR 		
					</strong><br><span class="contentTableReg">aminocaproic acid tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49411-051</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMINOCAPROIC ACID</strong> (AMINOCAPROIC ACID) </td>
<td class="formItem">AMINOCAPROIC ACID</td>
<td class="formItem">1000 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (WHITE) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">XP;A;20</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49411-051-30</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem">06/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA015197</td>
<td class="formItem">06/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Clover Pharmaceuticals Corp.
							(078398998)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>bba3bfb1-b56e-4370-8b68-25f18db3fc02</div>
<div>Set id: 2238c70f-b0b5-4755-896b-45b28777b217</div>
<div>Version: 4</div>
<div>Effective Time: 20150611</div>
</div>
</div> <div class="DistributorName">Clover Pharmaceuticals Corp.</div></p>
</body></html>
